Mirum Pharmaceuticals, Inc. Operating Cash Flow
Mirum Pharmaceuticals, Inc. (MIRM) reported Operating Cash Flow of -$273.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$44.25M, a 467.54% decline year-over-year.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$228.76M.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $6.07M.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $39.68M, a 896.01% increase year-over-year.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was $55.83M, a 440.70% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was $10.32M.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$70.94M.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$120.14M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 5 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 8 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$44.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$273.01M 10-Q · filed 2026-08-05 | -$266.95M derived: sum of 3 quarters · filed 2026-08-05 | -$227.27M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | -$228.76M 10-Q · filed 2026-05-06 | -$222.70M derived: sum of 2 quarters · filed 2026-05-06 | -$183.01M derived: sum of 3 quarters · filed 2026-05-06 | -$170.97M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $6.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $45.75M derived: sum of 2 quarters · filed 2026-02-25 | $57.79M derived: sum of 3 quarters · filed 2026-08-05 | $55.83M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $39.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $51.72M derived: sum of 2 quarters · filed 2026-08-05 | $49.76M 10-Q · filed 2025-11-04 | $44.69M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $12.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $10.08M 10-Q · filed 2026-08-05 | $5.01M derived: sum of 3 quarters · filed 2026-08-05 | $8.99M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | -$1.96M 10-Q · filed 2026-05-06 | -$7.03M derived: sum of 2 quarters · filed 2026-05-06 | -$3.04M derived: sum of 3 quarters · filed 2026-05-06 | -$6.85M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | -$5.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$1.08M derived: sum of 2 quarters · filed 2026-02-25 | -$4.89M derived: sum of 3 quarters · filed 2026-02-25 | $10.32M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $3.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $181.00K derived: sum of 2 quarters · filed 2025-11-04 | $15.39M 10-Q · filed 2025-11-04 | -$1.23M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-06-30 | -$3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $11.41M 10-Q · filed 2025-08-06 | -$5.21M derived: sum of 3 quarters · filed 2026-02-25 | -$23.43M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2024-03-31 | $15.21M 10-Q · filed 2025-05-07 | -$1.41M derived: sum of 2 quarters · filed 2026-02-25 | -$19.63M derived: sum of 3 quarters · filed 2026-02-25 | -$36.96M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | -$16.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$34.84M derived: sum of 2 quarters · filed 2026-02-25 | -$52.17M derived: sum of 3 quarters · filed 2026-02-25 | -$70.94M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | -$18.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$35.55M derived: sum of 2 quarters · filed 2024-11-12 | -$54.33M 10-Q · filed 2024-11-12 | -$88.60M derived: sum of 4 quarters · filed 2025-02-26 | |||
| 2023-06-30 | -$17.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$36.10M 10-Q · filed 2024-08-07 | -$70.38M derived: sum of 3 quarters · filed 2025-02-26 | -$96.40M derived: sum of 4 quarters · filed 2025-02-26 | |||
| 2023-03-31 | -$18.77M 10-Q · filed 2024-05-08 | -$33.77M 10-Q · filed 2023-05-04 | -$53.04M derived: sum of 2 quarters · filed 2025-02-26 | -$79.07M derived: sum of 3 quarters · filed 2025-02-26 | -$99.24M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | -$34.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$60.30M derived: sum of 2 quarters · filed 2025-02-26 | -$80.47M derived: sum of 3 quarters · filed 2025-02-26 | -$120.14M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | -$26.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$46.20M derived: sum of 2 quarters · filed 2023-11-02 | -$85.87M 10-Q · filed 2023-11-02 | -$119.01M derived: sum of 4 quarters · filed 2024-03-15 | |||
| 2022-06-30 | -$20.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$59.84M 10-Q · filed 2023-08-07 | -$92.99M derived: sum of 3 quarters · filed 2024-03-15 | -$127.19M derived: sum of 4 quarters · filed 2024-03-15 | |||
| 2022-03-31 | -$39.67M 10-Q · filed 2023-05-04 | -$72.82M derived: sum of 2 quarters · filed 2024-03-15 | -$107.02M derived: sum of 3 quarters · filed 2024-03-15 | -$147.22M derived: sum of 4 quarters · filed 2024-03-15 | |||
| 2021-12-31 | -$33.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$67.35M derived: sum of 2 quarters · filed 2024-03-15 | -$107.55M derived: sum of 3 quarters · filed 2024-03-15 | -$132.76M 10-K · filed 2024-03-15 | |||
| 2021-09-30 | -$34.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$74.40M derived: sum of 2 quarters · filed 2022-11-09 | -$99.61M 10-Q · filed 2022-11-09 | -$135.89M derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2021-06-30 | -$40.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$65.41M 10-Q · filed 2022-08-04 | -$101.69M derived: sum of 3 quarters · filed 2022-08-04 | -$119.14M derived: sum of 4 quarters · filed 2022-08-04 | |||
| 2021-03-31 | -$25.21M 10-Q · filed 2022-05-05 | -$61.49M derived: sum of 2 quarters · filed 2022-05-05 | -$78.94M derived: sum of 3 quarters · filed 2022-05-05 | -$95.93M derived: sum of 4 quarters · filed 2022-05-05 | |||
| 2020-12-31 | -$36.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$53.73M derived: sum of 2 quarters · filed 2022-03-09 | -$70.72M derived: sum of 3 quarters · filed 2022-03-09 | -$89.08M 10-K · filed 2022-03-09 | |||
| 2020-09-30 | -$17.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$34.45M derived: sum of 2 quarters · filed 2021-11-15 | -$52.80M 10-Q · filed 2021-11-15 | -$66.49M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | -$16.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$35.34M 10-Q · filed 2021-08-05 | -$49.04M derived: sum of 3 quarters · filed 2021-08-05 | -$64.26M derived: sum of 4 quarters · filed 2021-08-05 | |||
| 2020-03-31 | -$18.35M 10-Q · filed 2021-05-06 | -$32.05M derived: sum of 2 quarters · filed 2021-05-06 | -$47.27M derived: sum of 3 quarters · filed 2021-05-06 | -$55.29M derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2019-12-31 | -$13.70M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$28.92M derived: sum of 2 quarters · filed 2021-03-09 | -$36.94M derived: sum of 3 quarters · filed 2021-03-09 | -$39.36M 10-K · filed 2021-03-09 | |||
| 2019-09-30 | -$15.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$23.24M derived: sum of 2 quarters · filed 2020-11-12 | -$25.66M 10-Q · filed 2020-11-12 | ||||
| 2019-06-30 | -$8.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$10.44M 10-Q · filed 2020-08-06 | |||||
| 2019-03-31 | -$2.43M 10-Q · filed 2020-05-07 | ||||||
| 2018-12-31 | -$373.00K 10-K · filed 2020-03-12 | ||||||
| 2018-09-30 | -$19.00K 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |